Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status

Thompson, Eric M., Landi, Daniel, Ashley, David, Keir, Stephen T. and Bigner, Darell 2018, Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status, Journal of neuro-oncology, pp. 1-8, doi: 10.1007/s11060-018-2975-5.

Attached Files
Name Description MIMEType Size Downloads

Title Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status
Author(s) Thompson, Eric M.
Landi, Daniel
Ashley, David
Keir, Stephen T.
Bigner, Darell
Journal name Journal of neuro-oncology
Start page 1
End page 8
Total pages 8
Publisher Springer
Place of publication New York, N.Y.
Publication date 2018-08-17
ISSN 1573-7373
Keyword(s) BRAF
Bevacizumab
MEK inhibitor
Pleomorphic xanthoastrocytoma
Temozolomide
Tyrosine kinase inhibitor
Notes First Online Article
Language eng
DOI 10.1007/s11060-018-2975-5
Field of Research 1109 Neurosciences
1112 Oncology And Carcinogenesis
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2018, Springer Science+Business Media, LLC, part of Springer Nature
Persistent URL http://hdl.handle.net/10536/DRO/DU:30113277

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 23 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Mon, 10 Sep 2018, 14:09:23 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.